glp-1 small molecule agonist A small-molecule oral of the human glucagon-like peptide-1 receptor Potential oral small-molecule GLP-1R agonist.
Description
Although not thought to be directly influenced by obesity, lipoprotein (a) is an independent risk factor for cardiovascular disease that is determined by genetics
This is known as titrating doses
A new report by financial research companies Morningstar and PitchBook projected that the GLP-1 market will hit $200 billion by 2031 and that 16 new obesity drugs could emerge within the next five years
Martn ED, Snchez-Perez A, Trejo JL, et al
Spolcova A, Mikulaskova B, Holubova M, Nagelova V, Pirnik Z, Zemenova J, et al
